^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Nat Commun
    Title:

    PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

    Published date:
    12/07/2020
    Excerpt:
    This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti–PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n = 26), or durvalumab and trametinib given concomitantly (cohort B, n = 20) or sequentially (cohort C, n = 22) for patients with BRAF-wild type melanoma....Among the 11 patients with NRAS-mutant disease across cohorts B and C, 3 (27.2%) had PRs.
    DOI:
    10.1038/s41467-020-19810-w
    Trial ID:
    NCT02027961